Google Plus Facebook LinkedIn Twitter Vimeo RSS

Unilife inks $110M deal for EZMix syringe

By , - Last modified: April 9, 2013 at 10:39 AM

York County-based Unilife Corp. said today it has signed an agreement with a U.S. pharmaceutical company for Unilife's EZMix dual-chamber syringe, according to a news release.

Unilife anticipates generating revenue of up to $110 million during the 15-year customization and commercial supply agreement, the release stated.

The identity of the customer was not released for commercial purposes and because of confidentiality provisions in the agreement.

Unilife is a developer and commercial supplier of injectable drug delivery systems. Shares are traded in the United States on the Nasdaq under the ticker symbol UNIS.

More From This Industry

Write to the Editorial Department at

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy